Biomanufacturing Shift Focuses on Real-Time Sensing and AI Integration

Biomanufacturing facilities have historically operated bioreactors as black boxes, relying on offline assays that arrive hours after metabolic changes occur. Compound manufacturers report batch failure rates of roughly 5% to 10% on average for biologics and ingredient production, costing billions of dollars annually.

In 2020, the FDA reported that 62% of all drug shortages were caused by manufacturing and product quality problems.

Operators have set empirical inputs and monitored parameters such as pH, dissolved oxygen, and temperature while waiting for offline samples. Critical variables including amino acids, glucose, lactate, and ammonia were measured outside the reactor, creating delays that made real-time adjustments impossible.

New in-line measurement technologies now track substrates, by-products, and metabolites continuously inside the reactor without pulling samples. The data stream changes from periodic snapshots to a continuous multidimensional time series. When metabolic dynamics can be observed as they unfold, process control shifts from reactive corrections to predictive adjustments.

BCG estimated that integrating AI, digital twins, and advanced automation into traditional production systems can unlock an incremental 10% to 25% savings on conversion costs.

Each bioreactor has functioned as an isolated unit, with insights remaining at individual sites. A unified software layer allows sensing data, models, and process knowledge to reside in the same system across reactors, sites, and modalities. Each run supplies additional ground truth that improves subsequent predictions.